← Back to Search

Inhaled Isopropyl Alcohol vs Eucalyptus for Migraine-Related Nausea

N/A
Recruiting
Led By Jill Rau, MD, PhD
Research Sponsored by HonorHealth Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients 18 to 65 years old with nausea associated migraines at least twice per month
Be older than 18 years old
Must not have
Patients without a diagnosis of acute migraine
Patients <18 or >65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up ½ hour or to the end of treatment

Summary

This trial is testing if breathing in isopropyl alcohol can relieve nausea from migraines better than a placebo.

Who is the study for?
This trial is for adults aged 18 to 65 who experience nausea with their migraines at least twice a month. It's not suitable for those under 18 or over 65, or patients without an acute migraine diagnosis.
What is being tested?
The study aims to see if inhaling isopropyl alcohol vapors (IAV) is more effective and safer than a placebo, which in this case is diluted eucalyptus oil scent (IES), for relieving nausea during acute migraine attacks.
What are the potential side effects?
Potential side effects may include irritation of the airways, headaches, dizziness, or allergic reactions from inhaling the substances used in the trial.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 65 years old and get migraines with nausea at least twice a month.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have not been diagnosed with acute migraines.
Select...
I am younger than 18 or older than 65.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~½ hour, but likely less than 2 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and ½ hour, but likely less than 2 hours for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change of Severity of Nausea on Nausea Scale
Secondary study objectives
Side effects associated with interventional substance
Time to Clinically Relevant Nausea Change
Use of anti-nausea medication/Time to use of anti-nausea medication

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Isopropyl Alcohol VaporsActive Control1 Intervention
Isopropyl Alcohol 70%
Group II: Eucalyptus Oil ScentPlacebo Group1 Intervention
Eucalyptus oil diluted in mineral oil 1:20

Find a Location

Who is running the clinical trial?

HonorHealth Research InstituteLead Sponsor
25 Previous Clinical Trials
856 Total Patients Enrolled
Jill Rau, MD, PhDPrincipal InvestigatorHonorHealth Research Institute

Media Library

Isopropyl Alcohol Vapors Clinical Trial Eligibility Overview. Trial Name: NCT05175521 — N/A
Migraine Research Study Groups: Isopropyl Alcohol Vapors, Eucalyptus Oil Scent
Migraine Clinical Trial 2023: Isopropyl Alcohol Vapors Highlights & Side Effects. Trial Name: NCT05175521 — N/A
Isopropyl Alcohol Vapors 2023 Treatment Timeline for Medical Study. Trial Name: NCT05175521 — N/A
~13 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top